Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

March 20th 2025

A study of 200 patients with chronic lymphocytic leukemia (CLL) showed a lower rate of severe and serious adverse events among those treated with zanubrutinib compared with ibrutinib.

March 19th 2025

Researchers also highlighted the significance of TTNT-D as a real-world measure of treatment efficacy, noting it provides insight into both clinical and patient-centered outcomes.

March 11th 2025

Investigators found that lipid metabolism disruptions spark T-cell dysfunction in patients with chronic lymphocytic leukemia.

March 7th 2025

Treatment with liso-cel induced long-term complete remission rates and high undetectable minimal residual disease rates in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma following progression on Bruton tyrosine kinase inhibition and venetoclax.